Industry news

The top trends for med tech in 2017

Amirah Al Idrus / Fierce Medical Device

If 2016 was the year that med tech players bet big on emerging and exciting technologies, 2017 will be the year to buckle down, generate evidence of the new tech’s utility and find its niche in the industry. This year, numerous companies made moves in artificial intelligence, while GlaxoSmithKline and Verily threw down $715 million on a bioelectronics-oriented joint venture. Meanwhile, M&A and venture capital funding took a dip, and a few events highlighted current and future cybersecurity risks that may materialize as med tech becomes more connected.

Biotech IPO market slowdown—will it continue into 2017?

Ben Adams / Fierce Biotech

This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that almost all of the biotech IPOs that priced since the first quarter have broken issue, and were trading below their offer price.

2017 shaping up to be pivotal year for CAR-T and CRISPR therapies

Phil Taylor / Fierce Pharma

2017 is promising to be a pivotal year for synthetic biology as two landmark technologies—CRISPR/Cas9 and CAR-T—head toward critical milestones.

23 December 2016

Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

Neothetics, Inc.  (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of submental subcutaneous fat.

As the dust settles on Cures, what will it mean for biopharma R&D?

Phil Taylor / Fierce Pharma

At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017 and beyond.

The top biopharma trends of 2016, and looking ahead to 2017

Ben Adams / Fierce Biotech

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will bring.

Biosimilars Supporting Contract Manufacturers’ Growth

Eric Langer / BioPharm International

Biosimilars are finally becoming mainstream global products, including more than 20 having received approval in the European Union. The United States has been a prominent country lagging behind in its biosimilars approvals, with four approved by FDA. But many more approvals are on the way. This article examines impacts biosimilars are having on the biopharmaceutical contract manufacturing organization (CMO) sector. This includes capacity needs, and where biosimilars are requiring improved services, particularly related to biosimilarity testing and bioassays.

PWC “Top health industry issues of 2017: A year of uncertainty and opportunity”.

PWC

PwC Health Research Institute’s annual report highlights the forces that are expected to have the most impact on the healthcare industry in the coming year.

Patient connections will be key in pharma's year of 'opportunity,' PwC says

Beth Snyder Bulik / FiercePharmaMarketing

PwC's pharma and healthcare predictions for 2017 are out. And though, yes, next year may be "a year of uncertainty" with U.S. President-elect Donald Trump set to step in, it's also a year of "opportunity," the consultancy says.

Big Pharma’s business model is broken; New drug OKs plunged this year, highlighting an ugly reality

John Carroll / Endpoints News

End­points as­sesses the big bio­pharma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try. Big Pharma’s busi­ness model is bro­ken, so change it. When your ac­coun­tant tells you the busi­ness you’re run­ning is un­sus­tain­able, it’s a good idea to pay very, very close at­ten­tion to the de­tails. So it is with Big Pharma and drug de­vel­op­ment, a game which the largest play­ers in the in­dus­try have not mas­tered.